ConductScience.org, home

Comparison · NCT03377803-9f9045b0

VP-102 vs Placebo: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. VP-102 vs Placebo: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS). Trial comparisons, record NCT03377803-9f9045b0. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03377803-9f9045b0

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.540.460.618wilson
Risk in group 20.1340.08290.209wilson
Risk difference, group 1 minus group 20.4060.2960.499newcombe hybrid score
Risk ratio, group 1 over group 24.032.466.61log
Odds ratio, group 1 over group 27.594.0414.3log
Number needed to treat, for one more participant with the outcome on VP-102 than on Placebo2.4623.37from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1VP-102
VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days~VP-102: VP-102 Active will be administered via the applicator to Molluscum lesions~Applicator: Used to apply the topical film forming Active or Placebo to Molluscum.
81150OG000
Group 2Placebo
Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days~Placebo: Placebo to be applied via the applicator to Molluscum lesions~Applicator: Used to apply the topical film forming Active or Placebo to Molluscum.
15112OG001

Outcome

Type
PRIMARY
Title
Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS)
Description
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS).
Time frame
Day 1 (Baseline) compared to Day 84 (EOS)
Population
ITT Population

Source ClinicalTrials.gov

Trial

Title
Cantharidin Application in Molluscum Patients
NCT number
NCT03377803
Phases
PHASE3
Conditions
Molluscum Contagiosum
Interventions
VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102
Lead sponsor
Verrica Pharmaceuticals Inc.
Results first posted
2021-12-14

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03377803-9f9045b0